Exelixis (EXEL) vs Neurocrine Biosciences (NBIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Exelixis (EXEL) has outperformed Neurocrine Biosciences (NBIX) over the past year, gaining 47.5% versus a gain of 4.7%. Over five years, EXEL leads with a +167.8% price change compared with +37.2% for NBIX. Exelixis is the larger company by market cap ($14.46 billion vs $14.35 billion), about 1.0 times the size, while Neurocrine Biosciences is growing revenue faster (+21.4% vs +7.0%).
On valuation, Neurocrine Biosciences trades at a lower forward P/E (11.9x vs 13.8x for Exelixis). Exelixis converts more of its revenue into profit, with a net margin of 33.7% versus 16.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EXEL | NBIX |
|---|---|---|
| Share price | $58.35 | $141.15 |
| Market cap | $14.46B | $14.35B |
| 1-day change | -0.15% | -1.62% |
| YTD return | +33.33% | +1.16% |
| 1-year return | +47.46% | +4.72% |
| 5-year return | +167.83% | +37.24% |
| P/E ratio (TTM) | 18.41 | 20.70 |
| Forward P/E | 13.76 | 11.88 |
| EPS (TTM) | $3.17 | $6.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.32B | $2.86B |
| Revenue growth (YoY) | +6.98% | +21.45% |
| Net income (latest FY) | $782.57M | $478.60M |
| Gross margin | 96.39% | 98.18% |
| Operating margin | 37.59% | 21.64% |
| Net margin | 33.73% | 16.73% |
| 52-week high | $61.14 | $186.12 |
| 52-week low | $33.76 | $122.14 |
| Distance from 52-week high | -4.56% | -24.16% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | -6.55% | +46.86% |
| Average volume | 2.34M | 1.30M |
| Shares outstanding | 247.78M | 101.65M |
| Employees | 1,077 | 2,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EXEL has outperformed NBIX by 42.7 percentage points over the past year.
- Exelixis is more profitable, keeping 33.7 cents of every revenue dollar as net income versus 16.7 cents for Neurocrine Biosciences.
- Neurocrine Biosciences grew revenue faster in its latest fiscal year (+21.45% vs +6.98%).
About Exelixis
EXEL stock →Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,077 employees
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees
EXEL vs NBIX FAQ
Which is bigger, Exelixis or Neurocrine Biosciences?
Exelixis (EXEL) is larger, with a market capitalization of $14.46B compared with $14.35B for Neurocrine Biosciences (NBIX).
Which stock has performed better over the past year, EXEL or NBIX?
EXEL returned +47.46% over the past 12 months, compared with +4.72% for NBIX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, EXEL or NBIX?
EXEL has the lower trailing P/E at 18.4, versus 20.7 for NBIX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Exelixis and Neurocrine Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.